IMPORTANT PAXLOVID™ EUA DISPENSING INFORMATION FOR PATIENTS WITH MODERATE RENAL IMPAIRMENT

Attention Pharmacist:

Do not discard this page.

To dispense PAXLOVID dose (150 mg nirmatrelvir with 100 mg ritonavir) for moderate renal impairment, pharmacist should:

STEP ONE: Remove one of the 150 mg nirmatrelvir tablets from the morning dose and remove one of the 150 mg nirmatrelvir tablets from the evening dose of the blister card (see figure 1 below). The nirmatrelvir tablets that are removed should be the ones closest to the middle of the blister pack. Discard the removed tablets per state requirements or local guidelines.

![Figure 1: Remove the nirmatrelvir tablets circled in red from the blister card](image1)

STEP TWO: Affix the blister card with one sticker from the provided tear pad to carefully cover the empty blister cavities as shown in figure 2 below. The exact placement of this sticker is important to cover the empty blister cavities from the tablets. Ensure the sticker also covers the pre-printed dosing instruction that is on the blister card.

![Figure 2: Placement of sticker over empty blister cavities and pre-printed dosing instruction after removal of nirmatrelvir tablets](image2)

STEP THREE: Repeat steps one and two for every blister card in the carton (each carton contains five blister cards for a full 5-day dosing regimen).

See reverse side for additional instructions.
STEP FOUR: Affix one sticker from the provided tear pad to carefully cover over the pre-printed dosing regimen on the carton as shown in figure 3 below:

Figure 3: Placement of sticker over pre-printed dosing regimen on carton

Patients with moderate renal impairment should be instructed to take only one 150-mg nirmatrelvir tablet with one 100-mg ritonavir tablet together twice daily for 5 days. Patients with moderate renal impairment should be notified that their blister cards have been altered by their pharmacist to remove unneeded tablets.

How to obtain additional stickers: Pharmacies needing additional pads should contact C19therapies@amerisourcebergen.com.

For further information, including how to report adverse events and all medication errors, please refer to the EUA Fact Sheet for Healthcare Providers.